The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...

However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.

Sagimet Biosciences (SGMT) announced the completion of end-of-Phase 2 interactions with the U.S. Food and Drug Administration, supporting the ...

Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial. Investigators now have ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 ...

According to the company, Duravyu 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...